CGS 21680 exerts marked antidystonic effects in a genetic model of paroxysmal dyskinesia

European Journal of Pharmacology

Volumn 404, Issue 3, 2000, Pages 299-302

  Richter, Angelika ^a   Hamann, Melanie ^a   Bartling, Christiane ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Adenosine receptor agonist; Basal ganglia disorder; Dystonia; Movement disorders

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2 RECEPTOR AGONIST; CAFFEINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOREOATHETOSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DYSKINESIA; DYSTONIA; GENETIC MODEL; HAMSTER; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; STRESS;

ADENOSINE; ANIMAL; CHOREATIC DISORDERS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DYSTONIA; HAMSTERS; MODELS, GENETIC; PHENETHYLAMINES; RECEPTORS, PURINERGIC P1; STRESS, PSYCHOLOGICAL; SUPPORT, NON-U.S. GOV'T;

EID: 0034703569     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00627-0     Document Type: Article

References (18)

1. Abercrombie E.D., Keefe K.A., Difrischia D.F., Zigmond M.J. Differential effects of stress on in vivo dopamine release in striatum, nucleus accumbens and medial frontal cortex. J. Neurochem. 52:1989;1655-1658.
2. Demirkiran M., Jankovic J. Paroxysmal diskinesias: clinical features and classification. Ann. Neurol. 38:1995;571-579.
3. 2A receptors. Br. J. Pharmacol. 129:2000;1465-1473.
4. Fahn S. Medical treatment of dystonia. Tsui J.K.C., Calne D.B. Handbook of Dystonia. 1995;317-328 Marcel Dekker, New York.
5. Fahn S., Bressman S.B., Marsden C.D. Classification of dystonia. Fahn S., Marsden C.D., DeLong M.R. Dystonia 3. Adv. Neurol. vol. 78:1998;1-10 Lippincott-Raven, New York.
6. Ferre S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20:1997;482-487.
7. Fredholm B.B. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol. Toxicol. 76:1995;93-101.
8. 1 receptor interaction in the basal ganglia. Brain Res. Rev. 26:1998;258-273.
9. Löscher W., Fisher J.E. Jr., Schmidt D., Fredow G., Hönack D., Iturrian W.B. The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia? Movement Disord. 4:1989;219-232.
10. Löscher W., Fredow G. Effects of pharmacological manipulation of dopaminergic and cholinergic neurotransmission in genetically dystonic hamsters. Eur. J. Pharmacol. 213:1992;31-39.
11. Marsden C.D., Quinn N.P. The dystonias. Br. Med J. 300:1990;139-144.
12. 2 receptor binding in the genetically dystonic hamster. Neuroscience. 71:1996;927-936.
13. 2A receptors. Trends Pharmacol. Sci. 17:1996;364-372.
14. Popoli P., Pezzola A., Reggio R., Caporali M.G., de Carolis A.S. CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease. Eur. J. Pharmacol. 257:1994;R5-R6.
15. Rehders J.H., Löscher W., Richter A. Evidence for striatal overactivity in paroxysmal dystonia indicated by microinjections in a genetic rodent model. Neuroscience. 97:2000;267-277.
16. Richter A., Löscher W. The atypical neuroleptic, clozapine, exerts antidystonic activity in a mutant hamster model: comparison with haloperidol. Eur. J. Pharmacol. 242:1993;309-312.
17. Richter A., Löscher W. Pathophysiology of idiopathic dystonia: findings from genetic animal models. Prog. Neurobiol. 54:1998;633-677.
18. Todd R.D., Perlmutter J.S. Mutational and biochemical analysis of dopamine in dystonia. Mol. Neurobiol. 16:1998;135-147.